Literature DB >> 30911774

Underpowered or negative? A crucial distinction.

Ole L Dollerup1,2, Jonas T Treebak1, Niels Jessen3,4.   

Abstract

Keywords:  Clinical trial; Human; Hyperinsulinaemic–euglycaemic clamp; Insulin sensitivity; NAD+ metabolism; Nicotinamide riboside

Mesh：

Substances：

Year:  2019        PMID： 30911774     DOI： 10.1007/s00125-019-4853-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  4 in total

1.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

Authors:  S E Inzucchi; D G Maggs; G R Spollett; S L Page; F S Rife; V Walton; G I Shulman
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

2.  Insulin sensitivity and metabolic flexibility following exercise training among different obese insulin-resistant phenotypes.

Authors:  Steven K Malin; Jacob M Haus; Thomas P J Solomon; Alecia Blaszczak; Sangeeta R Kashyap; John P Kirwan
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-09-24       Impact factor: 4.310

3.  A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.

Authors:  Ole L Dollerup; Britt Christensen; Mads Svart; Mark S Schmidt; Karolina Sulek; Steffen Ringgaard; Hans Stødkilde-Jørgensen; Niels Møller; Charles Brenner; Jonas T Treebak; Niels Jessen
Journal:  Am J Clin Nutr       Date:  2018-08-01       Impact factor: 7.045

Review 4.  NAD+ metabolism as a target for metabolic health: have we found the silver bullet?

Authors:  Niels J Connell; Riekelt H Houtkooper; Patrick Schrauwen
Journal:  Diabetologia       Date:  2019-02-16       Impact factor: 10.122
  4 in total
  1 in total

1.  Underpowered or negative? A crucial distinction. Reply to Dollerup OL, Treebak JT, Jessen N [letter].

Authors:  Niels J Connell; Riekelt H Houtkooper; Patrick Schrauwen
Journal:  Diabetologia       Date:  2019-04-13       Impact factor: 10.122
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.